Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
What Is CJC-1295 And How Does It Work?
CJC-1295 is a synthetic peptide that mimics GHRH, binds to pituitary receptors, and stimulates growth hormone release, which then prompts the liver to produce more IGF-1. Researchers engineered it for extended activity, so it stays active far longer than natural GHRH, which breaks down within minutes.
There are two main forms. CJC-1295 With DAC (Drug Affinity Complex) uses a maleimide linker to bind serum albumin, extending its effective elimination half-life to about 6 to 8 days. That longer half-life allows weekly dosing. CJC-1295 Without DAC (also called Modified GRF 1-29) has a half-life of roughly 30 minutes, needs more frequent dosing, and produces sharper, more pulsatile GH release.
CJC-1295 is often combined with Ipamorelin, a GH secretagogue that acts on the ghrelin receptor, which is a separate pathway from GHRH. Clinics pair the two because they act on different receptors, yet no trial has tested the combination for weight loss in humans. CJC-1295 does not burn fat directly. It creates a hormonal environment that may support fat loss when you also maintain a caloric deficit and follow a consistent resistance-training program.1
Does CJC-1295 Actually Cause Weight Loss?
Current clinical evidence does not show a direct weight-loss effect from CJC-1295. A PubMed search finds no published human randomized trial showing that CJC-1295, Ipamorelin, or the combination causes weight loss as a primary endpoint.
The most cited human study, Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism, measured GH and IGF-1 responses in healthy adults. It did not measure weight, fat mass, or body composition. A single injection raised GH 2–10× and IGF-1 1.5–3× for days, yet the study did not assess weight loss and cannot be used as proof that CJC-1295 causes clinically meaningful weight loss.
Most weight-loss claims rely on growth hormone physiology and anecdotal reports rather than direct clinical evidence. CJC-1295 is not FDA-approved for weight loss, and outcomes vary widely. Any clinic or website that promises rapid fat loss from CJC-1295 alone deserves careful scrutiny. If you are considering CJC-1295, the first step is an honest, lab-based review of your health and goals. Get an honest, lab-driven assessment by booking a consultation with Ellie.
CJC-1295 Compared With GLP-1 Medications For Weight Loss
CJC-1295 and GLP-1 receptor agonists act on different hormone systems. CJC-1295 targets GHRH receptors in the pituitary, while GLP-1 agonists act on incretin receptors mainly in the pancreas and central nervous system. There is no receptor overlap, competitive binding, or known direct drug interaction between these classes.
The strength of the evidence differs sharply. GLP-1 receptor agonists have large Phase 3 trials. Semaglutide produced about 15% mean weight loss over 68 weeks in the STEP-1 trial, and tirzepatide produced about 21% mean weight loss over 72 weeks in SURMOUNT-1. CJC-1295 has no comparable weight-loss trial.
Their side-effect patterns also differ. GLP-1 agonists frequently cause nausea, vomiting, and diarrhea. CJC-1295 more often causes injection-site reactions, flushing, and headache, and long-term safety data is absent. GLP-1s are FDA-approved for weight management, while CJC-1295 is not approved for any indication. These therapies serve different roles: GLP-1s are evidence-based weight-loss medications, and CJC-1295 is an investigational compound that may support body composition goals under medical supervision.
What Results Can You Expect And When?
Most people see subtle internal changes before visible body changes. Deeper sleep and better recovery often appear within 1–4 weeks, while visible body-composition changes usually require 8–16 weeks of consistent use with resistance training and adequate protein intake.1
Several factors directly shape your results:
- Baseline health and hormone levels
- Diet quality and the degree of caloric deficit
- Consistency with resistance training
- Sleep quality, since averaging fewer than 6 hours per night can reduce peak GH pulses by 30–40%
- Product quality and dosing accuracy
Fewer than 30% of users see meaningful body-composition changes within the first eight weeks.1 Many treat CJC-1295 like a stand-alone weight-loss drug instead of a GH secretagogue that needs lifestyle alignment. To confirm that the peptide is actually working, IGF-1 testing at weeks 8–12 provides an objective measure of biological response.
What Are The Downsides Of CJC-1295? Side Effects And Risks
In the only published human trial (Teichman et al., 2006, n=64, 28 days), the most common adverse events were injection-site reactions such as pain, redness, and swelling, along with flushing and headache. All reported events were mild and transient. Mechanism-based risks include water retention, joint pain, carpal tunnel symptoms, and increased blood sugar, since sustained GH elevation promotes insulin resistance in liver and skeletal muscle.
Does CJC-1295 Cause Hair Loss? There is no published evidence linking CJC-1295 to hair loss. Anecdotal reports exist, yet this effect is not well documented and may relate to other hormonal or lifestyle factors.
Does CJC-1295 Decrease Testosterone? Current data does not show a testosterone-lowering effect. CJC-1295 acts on the GHRH receptor in the pituitary, not on gonadotropin pathways (LH or FSH) or androgen receptors, so it does not directly change testosterone production.
The longer-term risks require careful consideration. The longest published human trial lasted only 49 days. Researchers have not produced long-term safety data or carcinogenicity and reproductive-toxicity studies. There is also a theoretical cancer risk from chronically elevated IGF-1, supported by large cohort studies that link higher circulating IGF-1 to increased risk of colorectal, premenopausal breast, and prostate cancer.
The purity of products adds another layer of risk. Third-party testing of research peptides bought online has found large variation between labeled and actual peptide content, along with bacterial endotoxin contamination in some products. A qualified physician can order baseline labs, monitor IGF-1 and glucose, adjust dosing, and catch problems early. That level of oversight is not available when you purchase peptides online without supervision.
Who Should Avoid CJC-1295?
CJC-1295 does not suit every patient. The following groups should avoid it:
- Anyone with active cancer or a history of cancer, since GH/IGF-1 axis activation may promote tumor growth
- Pregnant or breastfeeding individuals
- People with uncontrolled diabetes, because GH impairs insulin sensitivity
- Anyone with active pituitary pathology
- Competitive athletes, since CJC-1295 appears under Section S2 of the WADA Prohibited List as a peptide hormone and growth factor, banned at all times
- Anyone unwilling to commit to diet, exercise, and sleep discipline
How Mirror Plastic Surgery Uses CJC-1295 Safely
Medical supervision changes peptide therapy from guesswork into a structured plan. Buying peptides online without guidance means no quality control, no accurate dosing, no monitoring, and no one checking for contraindications.
At Mirror Plastic Surgery, Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, Stanford Biodesign Innovation Fellow, oversees every peptide protocol. As a board-certified physician, he designs each plan around your labs and physiology and supervises treatment from start to finish. The process includes:
- A comprehensive 30–60 minute consultation that reviews medical history and health goals
- Baseline lab testing covering thyroid, liver, kidney, glucose, and hormone panels
- A personalized protocol based on your physiology rather than a generic template
- Quality-sourced peptides with batch testing for purity and sterility
- Ongoing monitoring and direct 24/7 text access to Dr. Akash for questions and adjustments
This level of oversight helps make peptide therapy safer and more effective. Explore Mirror Plastic Surgery’s peptide therapy offerings to see the full range of available protocols. Start with a thorough evaluation and lab testing by scheduling your appointment.
What Happens When You Stop Taking CJC-1295?
After you stop CJC-1295, GH and IGF-1 levels return to baseline within 1–2 weeks for the no-DAC form or 2–4 weeks for the DAC form.1 There is no documented crash or withdrawal pattern and no need for post-cycle therapy. The benefits fade as hormone levels normalize.
Body-composition changes last only if you maintain the training and nutrition that created them.1 Weight lost during a protocol can return if diet and exercise habits slip. A realistic maintenance plan, rather than indefinite peptide use, preserves results over time.
Frequently Asked Questions
Will CJC-1295 Make Me Lose Weight?
Current trials do not show that CJC-1295 causes weight loss on its own. At best, it may support fat loss indirectly by increasing GH and IGF-1 when you also maintain a sustained caloric deficit and follow a resistance-training program. Even with those pieces in place, results vary widely based on genetics, baseline hormone levels, sleep quality, and lifestyle adherence. This variability explains why anyone promising guaranteed or rapid weight loss from CJC-1295 alone is not accurately representing the science.
How Long Does It Take To See Results From CJC-1295?
Most users notice better sleep and faster recovery within 1–4 weeks. IGF-1 levels usually begin rising within 10–14 days and reach meaningful elevation around weeks 4–6. Visible body-composition changes typically require 8–16 weeks of consistent use with appropriate diet and resistance training.1
IGF-1 testing at weeks 8–12 is the clearest way to confirm a biological response. If IGF-1 has not increased by that point, the protocol is not working as intended. Possible causes include dose, product quality, injection timing, or an underlying thyroid issue.
What Are The Downsides Of CJC-1295?
As detailed in the side-effects section, documented adverse events include mild injection-site reactions, transient flushing, headache, and dizziness. Mechanism-based risks include water retention, joint pain, carpal tunnel symptoms, and elevated blood sugar due to GH’s counter-regulatory effects on insulin. Large cohort studies suggest a theoretical cancer risk from chronically elevated IGF-1, and the longest human trial lasted only 49 days, so long-term safety remains unknown. Research-grade peptides purchased online also carry contamination and mislabeling risks.
Does CJC-1295 Cause Hair Loss?
No published evidence links CJC-1295 to hair loss. Some people report hair thinning in online communities, yet this effect is not well documented or strongly supported by mechanism. Hair changes in people using multiple compounds may relate to other hormones, nutritional gaps, or additional substances rather than CJC-1295 itself. If you notice hair changes during any peptide protocol, a physician should review your full clinical picture.
Does CJC-1295 Decrease Testosterone?
CJC-1295 does not appear to lower testosterone. It acts on the GHRH receptor in the anterior pituitary and does not interact with gonadotropin pathways such as LH or FSH or with androgen receptors. No published human study has shown a consistent testosterone-lowering effect from CJC-1295. Men and women can use it without concern about direct testosterone suppression, as long as a physician monitors a full hormone panel.
Is CJC-1295 FDA-Approved?
CJC-1295 does not currently have FDA approval for any indication. Clinical development stopped after a Phase 2 trial participant died, which the attending physician attributed to pre-existing coronary artery disease, and no Phase 3 trial followed. In 2023, the FDA placed CJC-1295 in Category 2 of its interim 503A compounding bulks list because of potential safety signals; the nomination was withdrawn in September 2024, and the compound remains under Pharmacy Compounding Advisory Committee review. It is classified as a research chemical, and “research use only” labeling does not make it lawful for routine human consumption.
The Evidence-Based Path Forward
CJC-1295 does not function as a miracle weight-loss drug. The science shows that CJC-1295 reliably increases growth hormone and IGF-1, which may support body-composition goals when paired with disciplined nutrition, resistance training, and solid sleep.1
At Mirror Plastic Surgery, Dr. Akash Chandawarkar provides concierge-level peptide therapy grounded in evidence rather than hype. Every protocol starts with a detailed evaluation and lab testing, and you receive ongoing support directly from Dr. Akash throughout your treatment.
Disclaimer: CJC-1295 is not FDA-approved for any indication. Results vary. Medical supervision is required. This article is for informational purposes only and does not constitute medical advice.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
